Navigation Links
Pfizer Plans Regulatory Submissions of Bosutinib in Chronic Myeloid Leukemia
Date:12/3/2010

n order to deliver new options that target specific hematologic abnormalities and mutations, it is important to understand the molecular subtypes and genetic variations associated with hematologic cancers. Pfizer Oncology has biologics and small molecules in clinical development across a number of hematologic malignancies.

About Pfizer Oncology

Pfizer Oncology is committed to the discovery, investigation and development of innovative treatment options to improve the outlook for cancer patients worldwide.  Our strong pipeline, one of the most robust in the industry, is studied with precise focus on identifying and translating the best scientific breakthroughs into clinical application for patients across a wide range of cancers. Pfizer Oncology has biologics and small molecules in clinical development and more than 100 clinical trials underway. By working collaboratively with academic institutions, individual researchers, cooperative research groups, governments, and licensing partners, Pfizer Oncology strives to cure or control cancer with breakthrough medicines, to deliver the right drug for each patient at the right time.   For more information please visit www.Pfizer.com.  

DISCLOSURE NOTICE: The information contained in this release is as of December 3, 2010. Pfizer assumes no obligation to update  forward-looking statements contained in this release as the result of new information or future events or developments.

This release contains forward-looking information about certain potential indications for bosutinib, an oncology product candidate, including their potential benefits and the planned timing of regulatory submissions for such indications, that involves substantial risks and uncertainties. Such risks and uncertainties include, among other things, the uncertainties inherent in research and development, including with regard to the pending 24-month dat
'/>"/>

SOURCE Pfizer Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pfizer Announces Positive Phase 3 Trial Results for Axitinib in Patients With Previously-Treated Metastatic Renal Cell Carcinoma (mRCC)
2. Pfizer Launches New Advil® Congestion Relief and Offers 100 Holiday Shoppers Literal Decongestion From Black Friday Crowds
3. Pfizer Launches Global Centers for Therapeutic Innovation, a Network of Research Partnerships, With University of California, San Francisco
4. Amgen, Pfizer, and World-Class Professional Golfer Phil Mickelson Announce Partnership
5. Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference
6. Pfizer Declares an 18-Cent Fourth-Quarter 2010 Dividend
7. Pfizers Lyrica® (Pregabalin) Capsules CV Receives Approval for Treatment of Peripheral Neuropathic Pain In Japan
8. Pfizer Commences Tender Offer for All Outstanding Shares of King Pharmaceuticals, Inc.
9. Pfizer Enters Into Agreement to Acquire 40 Percent Stake in Teuto in Brazil
10. Biocon and Pfizer Enter Into Global Commercialization Agreement
11. Pfizer Oncology To Present New Clinical Data Across Ten Tumor Types and Multiple Molecular Targets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... MENLO PARK, Calif. , Aug. 19, 2014 ... company") announced today a protocol amendment to allow for expanded ... the U.S. Food and Drug Administration (FDA) and that a ... opened at three clinical trial sites in the ... proceeds of US$2.9 million have been raised through warrant exercise ...
(Date:8/19/2014)... 19, 2014 ,Weight Loss- Market ... 2014, report provides comprehensive insights about phase III pipeline ... objective of the report is to establish the understanding ... drugs across the different countries and regions. While the ... report also provides details on the drug master filings ...
(Date:8/18/2014)... and HERZLIYA-PITUACH, Israel , Aug. 19, 2014 ... North Premier, Stockholm : "IMNP"), a biotechnology ... application to list its common stock on the NASDAQ Capital ... unit of the NASDAQ OMX Group. IMMUNE,s common stock is ... the opening of trading on August 21, 2014 under the ...
Breaking Medicine Technology:DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 2DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 3DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 4DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 5DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 6DelMar Pharmaceuticals Provides Update on Glioblastoma Clinical Trial and Results of Warrant Tender Offer 7Weight Loss Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 2Weight Loss Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 3Weight Loss Market Analysis, Global API Manufacturers and Phase III Pipeline Assessment, 2014 4Immune Pharmaceuticals Announces Approval for Listing on the NASDAQ Capital Market 2Immune Pharmaceuticals Announces Approval for Listing on the NASDAQ Capital Market 3Immune Pharmaceuticals Announces Approval for Listing on the NASDAQ Capital Market 4
... Dec. 27, 2011 Neuralstem, Inc. (NYSE Amex: ... Food and Drug Administration to advance to Phase Ib in ... NSI-189, for the treatment of major depressive disorder ... the drug in depressed patients. NSI-189 is a proprietary new ...
... Dec. 27, 2011 /PRNewswire-Asia/ -- China Botanic Pharmaceutical ... Botanic" or the "Company"), a developer, manufacturer and ... Medicines ("TCM") in China, today announced that the ... 66th PHARMCHINA fair ("the Fair") recently held in ...
Cached Medicine Technology:Neuralstem's NSI-189 Trial in Major Depressive Disorder Receives FDA Approval to Advance to Phase Ib 2Neuralstem's NSI-189 Trial in Major Depressive Disorder Receives FDA Approval to Advance to Phase Ib 3Neuralstem's NSI-189 Trial in Major Depressive Disorder Receives FDA Approval to Advance to Phase Ib 4China Botanic Exhibits All-Natural Anti-depressant Products at the 66th PHARMCHINA Fair 2China Botanic Exhibits All-Natural Anti-depressant Products at the 66th PHARMCHINA Fair 3
(Date:8/20/2014)... (PRWEB) August 20, 2014 The ... a five-year, $1.24 million Science Education Partnership Award ... to support NAHN’s collaborative project with the Hispanic ... Health Careers. , This collaborative NIH R25 program ... cultural and linguistic diversity among health professionals by ...
(Date:8/20/2014)... New Jersey (PRWEB) August 20, 2014 ... meeting the needs of an estimated tens of thousands ... of the new Bill A3525—a bill that would expand ... to grow their own cannabis—earlier this summer by State ... training for medicinal quality marijuana is growing. , To ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 Verndale is ... Inc. 500|5000 list; an exclusive list ranking the fastest-growing ... are ranked according to their yearly percentage revenue growth ... 8th time on the Inc. 5000 list where it ... Company, Verndale offers its clients a wide range of ...
(Date:8/20/2014)... B. E. Smith, the only full-service ... been retained to lead a national chief operating ... in Hermiston, Ore. The top executive search firm ... recently placed more than 900 healthcare executives into organizations. ... progressive, not-for-profit healthcare organization serving a population of more ...
(Date:8/20/2014)... Biosimilars, which are similar versions of ... abbreviated process, could reap billions in health care ... Inc.’s (AIS) Specialty Pharmacy News offers coverage of ... and Drug Administration’s (FDA) recent acceptance of a ... Drugmaker Sandoz said July 24 that the FDA ...
Breaking Medicine News(10 mins):Health News:National Association of Hispanic Nurses (NAHN) Receives Five-Year Federal Grant from the National Institutes of Health (NIH) 2Health News:National Association of Hispanic Nurses (NAHN) Receives Five-Year Federal Grant from the National Institutes of Health (NIH) 3Health News:Oaksterdam University to Host Four-Day Educational Marijuana Horticultural Seminar Aug 23-26; Training Fills Information Gap for Medical Marijuana Caregivers and Patients 2Health News:Oaksterdam University to Host Four-Day Educational Marijuana Horticultural Seminar Aug 23-26; Training Fills Information Gap for Medical Marijuana Caregivers and Patients 3Health News:For the 8th Time, Verndale Has Been Honored on the Inc. 5000 List 2Health News:Good Shepherd Health Care System Retains B. E. Smith to Recruit New COO 2Health News:Good Shepherd Health Care System Retains B. E. Smith to Recruit New COO 3Health News:AIS Newsletter Tracks Latest Developments in Biosimilars Market as FDA Accepts First Application 2Health News:AIS Newsletter Tracks Latest Developments in Biosimilars Market as FDA Accepts First Application 3
... Company ... driving growth of EMR business, MARKHAM, ON, Feb. ... (TSX-V: NGH), one of North,America,s fastest growing healthcare software ... Helper business to Netsmart,Technologies Inc., a leading provider of ...
... a response in the adult brain , , FRIDAY, Feb. 29 ... ga-ga when they see a baby? , Scientists report ... up a specific region of the adult brain associated with ... looked at another adult face, suggesting there,s a neural basis ...
... BOTHELL, Wash., Feb. 29 Nastech,Pharmaceutical Company Inc. ... will,host a conference call with investors and security ... Eastern time (8:30 a.m. Pacific time) to,discuss the ... in the live conference call, U.S. residents should,dial ...
... quantify heritability of the disease , , FRIDAY, Feb. 29 (HealthDay ... chronic bronchitis, genes also play a major role in the ... which analyzed data on more than 40,000 twins born in ... percent of the risk for chronic bronchitis and that 14 ...
... published in the February issue of Injury Prevention estimates ... schools in 2005-2007 were directly related to an action ... or disciplinary committee. , Researchers in the Center for ... analyzed data from the 2005-2006 and 2006-2007 National High ...
... under 60 survived longer than people who had single ... double lung transplant leads to longer survival than a ... are in the final stages of chronic obstructive pulmonary ... lung transplants are both recognized as treatment options for ...
Cached Medicine News:Health News:Nightingale announces US$12.3 million sale of its Therapist Helper business 2Health News:Nightingale announces US$12.3 million sale of its Therapist Helper business 3Health News:Nightingale announces US$12.3 million sale of its Therapist Helper business 4Health News:Babies Really Can Light Up Your Life 2Health News:Babies Really Can Light Up Your Life 3Health News:Nastech Pharmaceutical Company Inc. to Hold Conference Call to Discuss Corporate Restructuring and Future Strategy on Monday, March 3, 2008 2Health News:Genetic Factors for Smoking Boost Chronic Bronchitis Risk 2Health News:When the rules of the game are broken: Research studies sports injuries related to illegal activity 2Health News:Double Lung Transplant Better for Younger COPD Patients 2
The Redi-glaze spectacle magnifier is an aspheric lens, glazed into a standard Keeler LVA frame....
This set is designed to introduce the low vision practitioner to the Keeler telescopic system....
... Featuring up to 20 ... examination in the vertical, ... plus the option to ... corneal transillumination., ,Filters include ...
Comes complete in its own carrying case. There are 24 lenses, 13mm diameter -6D to +6D in 0.5D steps. Mounted in tough, yet light alloy frame....
Medicine Products: